Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

AVP BioPharma Consult ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   14.3% 9.7% 15.3% 9.8% 12.0% 12.3% 21.1% 21.1%   Credit score (0-100)   16 25 12 24 19 19 5 5   Credit rating   BB BB BB BB BB BB B B   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,463 1,107 1,201 1,125 1,009 1,169 0.0 0.0   EBITDA   409 250 340 194 145 312 0.0 0.0   EBIT   408 244 334 194 140 312 0.0 0.0   Pre-tax profit (PTP)   409.9 243.3 335.0 190.8 137.9 307.2 0.0 0.0   Net earnings   319.7 189.8 260.7 148.4 106.2 237.8 0.0 0.0   Pre-tax profit without non-rec. items   410 243 335 191 138 307 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   17.5 11.4 5.3 5.3 0.0 0.0 0.0 0.0   Shareholders equity total   375 295 346 294 225 323 23.1 23.1   Interest-bearing liabilities   2.8 1.7 1.7 1.6 2.2 10.1 0.0 0.0   Balance sheet total (assets)   480 479 516 498 387 504 23.1 23.1   Net Debt   -57.6 -300 -224 -300 -266 -235 -23.1 -23.1     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,463 1,107 1,201 1,125 1,009 1,169 0.0 0.0   Gross profit growth   45.6% -24.4% 8.5% -6.3% -10.4% 15.9% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   480 479 516 498 387 504 23 23   Balance sheet change%   47.7% -0.2% 7.9% -3.5% -22.3% 30.2% -95.4% 0.0%   Added value   408.8 249.8 340.1 193.6 139.7 312.3 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   17 -12 -12 0 -11 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   27.9% 22.0% 27.8% 17.2% 13.9% 26.7% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   102.1% 51.1% 67.5% 38.2% 31.7% 70.2% 0.0% 0.0%   ROI %   162.5% 72.3% 103.9% 60.0% 53.6% 111.7% 0.0% 0.0%   ROE %   127.5% 56.6% 81.4% 46.4% 40.9% 86.7% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   78.2% 61.6% 66.9% 59.0% 58.2% 64.0% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -14.1% -120.1% -65.8% -154.9% -183.4% -75.3% 0.0% 0.0%   Gearing %   0.7% 0.6% 0.5% 0.5% 1.0% 3.1% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   51.6% 63.1% 37.9% 174.6% 135.1% 94.0% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   4.5 2.5 3.0 2.4 2.4 2.8 0.0 0.0   Current Ratio   4.5 2.5 3.0 2.4 2.4 2.8 0.0 0.0   Cash and cash equivalent   60.4 301.7 225.5 301.5 268.0 245.2 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   358.5 274.4 341.6 290.0 225.3 323.1 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   409 250 340 194 140 312 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   409 250 340 194 145 312 0 0   EBIT / employee   408 244 334 194 140 312 0 0   Net earnings / employee   320 190 261 148 106 238 0 0